MILESTONE PHARMACEUTICALS ENROLLS FIRST CANADIAN STUDY PARTICIPANT IN REVERA-301 PHASE 3 PIVOTAL TRIAL EVALUATING ETRIPAMIL NASAL SPRAY FOR AFIB-RVR

Reuters · 3d ago

Please log in to view news